Phase 2 N=25 Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression
Panic Disorder · Major Depressive Disorder
Primary: Panic Disorder Severity Scale (PDSS) — 6; 1 responders
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)
Depersonalization Disorder
Primary: Cambridge Depersonalization Scale (CDS) — 6 responders (>50% reduction in CDS score)
Phase 2 N=128 Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Lung Cancer
Primary: Determine the Clinical Sensitivity and Specificity of the Biomoda CyPath™ Early Lung Cancer Detection Assay Using Sputum Specimens From Two Cohorts of Participants and…
Phase 2 N=62 Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome
Overactive Bladder
Primary: Mean Change of the Total Frequency Per 3 Days — -4.64; -0.19 Frequency per 3 days
Phase 2 N=60 AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Primary: Response Rate (Complete and Partial) 2 Separate Cohorts of Relapsed NSCLC Cohort A: Pts Who Have Received Prior Chemo w/o Ever Having Received Bevacizumab. Cohort B: Pts…
Phase 2 N=52 AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
Leukemia, Myeloid, Acute
Primary: Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML — 240 mcg/kg
Phase 2 N=172 Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Inflammation Associated With Cataract Surgery
Primary: Anterior Chamber Cell Count at Day 8 Post-Treatment — 50; 51.8; 60.3 percentage of patients with ACC clearing
Phase 2 N=14 Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)
Crohn's Disease
Primary: Number of Participants With Improved in Disease Activity — 0 participants
Phase 2 N=45 Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Mean Percentage Change From Baseline in Spleen Volume at Week 24 — -14.9 Percentage change
Phase 2 N=12 Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC
Neoplasms, Breast
Primary: Number of Participants With Intolerable Toxicities in Phase I of the Study — 1 Participants
Phase 2 N=120 Effect of Valsartan on Carotid Artery Disease
Carotid Artery Diseases · Atherosclerosis
Primary: Change in the Mean Vessel Wall Area (VMA) of the Carotid Bulb From Baseline to 2 Years — -6.7; 3.4 mm2
Phase 2 N=10 Differential Effects of Zolpidem Versus Ramelteon in Burned Children
Sleep · Burns
Primary: Polysomnography Data — 373; 346 minutes
Phase 2 N=14 Artificial Pancreas Control System in an Inpatient Setting
Type I Diabetes Mellitus
Primary: Mean Percent of Time in Target Blood Glucose Range — 62.4 percentage of time
Phase 2 N=28 Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
Alzheimer's Disease · Frontotemporal Dementia
Primary: Qualitative Amyloid Image Assessment — 2; 1; 8; 4 participants
Phase 2 N=50 Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in Children
Pain
Primary: Procedural Pain Intensity Score — 3.1 units on a scale